



Date:

Curriculum Vitae and List of Publications
Dr. Nimer Assy

A. Curriculum Vitae

1. Personal Data

Identity or Passport Number: 57009193

Place of Birth: Fassouta, Upper Galile, Israel

Date of Birth: 01.09.1961

Date of Immigration

Family Status: Married +5

Nationality: Israeli

Work Address: Galil Medical Center, Nahariya, Internal Medicine A

Permanent Address: Fassouta, 251700 Western

Galil

Work **☎:** 97249107748

Work Fax: 97249107158

Home **☎:** 0507887915

E-mail: nimera@gmc.gov.il

Army Service, Years

2. Education, Certificates and Degrees

From-To	Institute	Area of Specialty	Degree
1987	University of Louvain (UCL), Belgium		MD
1994	Rambam Medical Center	Internal Medicine	Specialty
	University of Manitoba, Canada	Hepatology	Fellowship
	University of Western Ontario, Canada	Liver transplant	Fellowship

Doctoral Thesis: Diabetic Nephropathy

Supervisor: Professor Rahier, University of Louvain (UCL), Belgium

Post doctorate research:



Supervisor

3. Positions Held:

From-To	Institute	Research Area	Title
	Galil Medical Center, Nahariya, Internal Medicine A	24 weeks for fourth year students	Clerkship
	Galil Medical Center, Nahariya, Internal Medicine A	4 weeks for sixth year students	clerkship
2011-2014	Azrieli Medical School, BIU	Bioenergetics course	Course coordinator
2011-2021	Azrieli Medical School, BIU	Hepatology lectures	
2012-	Azrieli Medical School, BIU	Interviews for student admission	

4. Academic Administrative Positions Held: (Head of Department, Dean, Member of Academic Committees, etc.).

From-To	Institute	Position
2011-	Azrieli Medical School, BIU	Associate Professor
2007-2010	Technion	Senior lecturer
2015-	Galil Medical Center, Nahariya, Internal Medicine A	Department head

5. Public Scientific Activities Outside the University (Positions held in Scientific Institutions, Communal Services and their Application to your Scientific work, Editing Scientific Journals).

From-To	Type of Activity or Appointment
2007-2014	Ziv Medical Center, in charge of the liver services
2011-2015	Member of the Liver Committee of the Ministry of Health
	Head of the Maccabi Health Clinic in the village of Fassouta
	Advisor on liver health for Clalit and Maccabi Health Services



	Member of the Mortality Committee of the Ministry of Health
	Member of the Fellowship Committee for the advancement of physicians Galil Medical Center
	Head of the Student Health Committee, Azrieli School of Medicine Bar-Ilan University
	Student entrance examiner for the Azrieli School of Medicine Bar-Ilan University
	Examiner for a Master's degree, Azrieli School of Medicine Bar-Ilan University
	Examiner for a PhD degree, Azrieli School of Medicine Bar-Ilan University
	Chairman of the Recognition Committee for Scientific Council Internships
2012-2015	"Health basket" consultant in the liver field
2014-	Member of the National Council for Liver Diseases and Nutrition
	Member, Mapping of the Physicians Reserve Committee, Galil Medical Center
	Examiner in Phase I and Phase II exams

6. CONFERENCES

1. Participation in organizing conferences

1. Nazareth meeting for the world hepatitis awareness day-2009
2. Involvement in organization of all IASL conferences from 2007-2011
3. First International liver meeting in The Galilee, Ramot, Tiberias May 13-14, 2010 (invited speakers from France and Canada attended)
4. EASL Clinical School in Jerusalem, Israel May 15, 2011. Chairman of a session on resection, ablation, and liver transplantation of hepatocellular carcinoma
5. Kenes Biorefuhah -Tel Hay Oct 25-2011: Chairman, member of the organizing committee, Tal-Hai College; Kiryat Shmoneh Oct 25, 2011

2. a. Plenary or invited talks



National Talks:

More than 30 oral presentations at the Israeli (IASL) Liver Meeting

- Northern Committee for Diabetes, Obesity, and Hypertension
- Sept 21-2011 Dan Carmel, Haifa: Fatty liver as a cardiovascular risk factor
- DOT 2009: Fatty liver disease. Hilton, Tel-Aviv
- DOT 2010; Soft drink consumption (fructose) and fatty liver. Tel Aviv
- IASL: Pharmacological therapy in NAFLD-atherosclerosis. Tel-Aviv, 2010
- Liver Meeting – Northern Committee (2007-2011): (HBV, fatty liver, HCV)

International Invited talks:

- **China, University of Peking, July 2019:** IGF-1 as a liver reserve assessment tool in Hepatocellular Carcinoma, Belt & Road International Conference on Hepatobiliary Carcinoma and Infectious Diseases (BRICHID)
- EPS Global 1ST International Conference of microbes, WCM1 -
2011 July 30-Aug 1, 2011, Beijing China. Vitamin D and chronic liver disease
- First world congress of viruses and infections (WCV1-2010).
- Busan; Korea July 31-august 3, 2010:** Hepatitis C and the Metabolic Syndrome: Chairman of session (3 hours) on hepatitis B
- EASL: European association for the study of the Liver; main lecture: oral presentation: Vitamin D supplements improve SVR in chronic hepatitis C in naïve patients treated with Peg interferon alpha and ribavirin, **Vienna April, 2010**
- “EHRLICH II - 2nd World Conference on Magic Bullets”
Celebrating the 100th Anniversary of the Nobel Prize Award to Paul Erlich held in **Nürnberg, Germany, October 3–5, 2008.** Presented Talk: “The changes in renal function after a single dose of intravenous Furosemide in patients with compensated liver cirrhosis”
- Satellite Symposium: Prospects for Improved Liver Disease Management in Chronic Hepatitis B; personal Approach of patients with HBV: "A day in the life of Dr Assy N." EASL: **Berlin 2004**

b. Contributed Talks and Abstracts



1. **Assy N**, Hochberg Z, Amit T, Enat R and Baruch Y. Growth hormone stimulated insulin like growth factor 1 (IGF-1) and binding protein-3 in liver cirrhosis. Hepatology (AASLD) 1994.
2. Baruch Y, **Assy N**, Amit T, and Hochberg Z. Spontaneous pharmacokinetics of growth hormone in liver cirrhotic patients. (EASL) 1996.
3. **Assy N**, Rosser BG, Graham GR and Minuk GY. Risk of sedation for upper Gastrointestinal endoscopy exacerbating sub clinical hepatic encephalopathy in patients with cirrhosis. Canadian Digestive Diseases Week. Banff. Canada 1996.
4. **Assy N**, KDE Kaita, D Mymin, C Levi, and GY Minuk. Fatty infiltration of the liver in hyperlipidemic patients. Hepatology (AASLD) 1996.
5. **Assy N**, NM Pettigrew, SS Lee, RK Chaudhary, J Johnson, and GY Minuk. Are chronic hepatitis C viral Infections more benign in patients with hemophilia? Hepatology (AASLD) 1996.
6. Gong WY, **Assy N**, M Zhang, and Minuk GY. Arrested hepatocyte proliferation following partial hepatectomy in rats. Hepatology (AASLD) 1996.
7. **Assy N**, and Adams PC. Predictive value of family history in the diagnosis of hereditary hemochromatosis. Canadian Digestive Diseases Week, Quebec 1997.
8. **Assy N**, Adams PC. Predictive Value of family history in the diagnosis of hereditary Hemochromatosis. Can J Gastroenterology Vol 11 suppl A (S70) 1997.
9. Baruch Y, **Assy N**, Krasik A, and Shoshany G. The effect of vascular endothelial growth factor (VEGF) on liver growth. Hepatology (AASLD) 1997.
10. **Assy N**, Hochberg Z, Enat R, and Baruch Y. Prognostic value of GH-stimulated insulin-like growth factor -1 (IGF-1) and its binding (IGBP-3) generation in patients with compensated and decompensated liver cirrhosis. Hepatology (AASLD) 1997.
11. **Assy N**, YW Gong, M Zhang, NM Pettigrew, D Pashniak and GY Minuk. The use of proliferating cell nuclear antigen (PCNA) m RNA and protein levels as a marker of liver regeneration following partial hepatectomy in rats. Hepatology (AASLD) 1997.
12. **Assy N**, Minuk GY, Myers P, Simon V, and Ghent CN. Immunosuppression withdrawal in stable liver transplant recipients. Transplantation 1997.
13. **Assy N**, Hoffman R, Brenner B, and Baruch Y. Budd-Chiari syndrome associated with factor V Leiden mutation: Hepatology (AASLD) 1998.



14. **Assy N**, Hoffman R, Lanir N, Brenner B, Baruch Y. Budd-Chiari syndrome associated with factor V Leiden mutation: A report of 6 patients. 1998 (IASLD).
15. **Assy N**, Spira G, Paizi M, Shankar L, Kraizer Y, Cohen T, Neufeld G, Dabbah B, and Baruch Y. Effect of vascular endothelial growth factor on hepatic regenerative activity following partial hepatectomy in rats. Hepatology 1998 (AASLD).
16. **Assy N**, Pruzansky Y, Gaitini D, Hochberg Z, Enat R, and Baruch Y. Changes in insulin-like growth factor-1 release after growth hormone administration in patients with different grades of liver cirrhosis. Hepatology 1998 (AASLD).
17. Zhang M, Gong Y, **Assy N**, and Minuk GY. Inhibition of alpha-fetoprotein gene expression and cell proliferation by muscimol, a gamma aminobutyric acid receptor agonist, in a human hepatocellular carcinoma. Hepatology 1998 (AASLD).
18. Spira G, Kraizer Y, Paizi M, and **Assy N**. Vascular endothelial growth factor and respective monoclonal antibodies can modulate liver cell proliferation following partial hepatectomy in rats. Hepatology 1999 (AASLD).
19. **Assy N**, Abassi Z, and Hussein O. Orlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis NASH). (IASL Eilat 2000).
20. **Assy N**, Gorenberg M, Awawdeh M, and Lerman A. Clinical Implication of DMSA uptake by the kidneys in cirrhotic patients with clinically normal renal function. Hepatology 2001A (Boston, AASLD).
21. **Assy N**, Kayal M, Mejirisky Y, Gorenberg M, Husseion O, and Schlesinger S. The Changes in renal function after a single dose of intravenous furosemide in patients with compensated liver cirrhosis. EASL (Berlin 2004).
22. **Assy N**, Lasri E, Grozovski M, Svalb S, Hussein O. Antioxidative liver enzymes fail to contain oxidative stress in nonalcoholic fatty liver disease in rats on different dietary fatty acids. (IASL; Eilat 2004).
23. **Assy N**, Shynin I, Mejirisky Y, Shen-Orr T, Mason T. Abnormal IGF-1 response to GH administration in patients with NAFLD. IASL; Eilat, 2004.
24. Hussein O, Grozovski M, Lasri E, Slab S, **Assy N**. "Monounsaturated fats decrease hepatic lipid content in nonalcoholic fatty liver diseases in rats", 15th International Symposium on Drugs Affecting Lipid Metabolism. October 24- 27, 2004, Venice, Italy, pp.99-99
25. **Assy N**, Schlesinger S, Hussein O. Elevated plasma protein C correlates with the presence of fatty liver (NASH and NAFLD). (IASL; Eilat 2005)



26. **Assy N**, Bekirov I, Mejiritsky Y, Solomon L, Szvalb A. Association between thrombotic risk factors and extent of fibrosis in patients with nonalcoholic fatty liver disease. IASL; Eilat 2005
27. **Assy N**, Grozovski M, Bersudsky I, Szvalb S and Hussein O. Effect of Insulin Sensitizing Agents, in combination with Ezetimibe, and Valsartan in rats with metabolic syndrome and fatty liver. Falk Symposium. Berlin 2005, and Eilat, 2006.
28. **Assy N**, Davidov V, Grozovski M, and Mijiriski Y. Protein C Activity Predicts NAFLD independently of classic risk factors, metabolic syndrome, and C-reactive protein. EASL 2006, Vienna.
29. **Assy N**, Pruzansky Y, Hochberg Z, Gaitini D, Shen Orr Z, and Baruch Y. Blunted IGF-1 responsiveness to GH administration in decompensated cirrhosis: Correlation with MELD and Child score but not with portal hypertension and malnutrition. IASL; Tiberias, 2007
30. Beniashvili Z, Hussein A, Dabush S, Hino B, and **Assy N**. HBV DNA levels at different clinical stages of chronic HBV (CHB). IASL; Mars, Tiberias 2007.
31. **Assy N**, Pruzansky Y, Gaitini D, Shen Orr Z, Hochberg Z, Minuk GY, and Baruch Y. Growth hormone-stimulated IGF-1 generation in cirrhosis reflects hepatocellular dysfunction. Falk Symposium; Dresden, Germany: Oct 2007
32. Beniashvilli Z, Grozovski M, Daboush S, Erdstein P and **Assy N**. "The use of new normal ALT values differentiates better HBeAg (-) chronic hepatitis B from inactive carrier state. The 58th Annual Meeting of the American Association for the Study of the Liver Diseases. November, 2007, Boston, Massachusetts, (USA).
33. Shatil T, Korem S, **Assy N**, Beniashvili Z, Grozovski M. "The effect of antidiabetic agents on hepatic retinol binding protein 4 expression and lipid metabolism in rats with non-alcoholic fatty Liver undergoing partial hepatectomy" The 12th Annual meeting of the Israeli Society for Research, Prevention and Treatment of Atherosclerosis in conjunction with the Frontiers in Cardiovascular Science, 18-21 Oct, 2007, Eilat, Israel
34. Hussein O, Abu Gabai K, Grozovski M, Bersudsky I, **Assy N**, Karry R, Aviram M. "The effect of insulin sensitizers (rosiglitazone and metformin), ezetimibe and valsartan (each alone or in combination) on plasma paraoxonase activity and mRNA expression in experimental rat non - alcoholic fatty liver disease" The 12TH Annual meeting of the Israeli Society for Research, Prevention and Treatment of



Atherosclerosis in conjunction with the Frontiers in Cardiovascular Science, 18-21 October, 2007, Eilat, Israel

35. Grozovski M, Shatil T, Korem S, Beniashvili Z, **Assy N**. "Increased serum and hepatic RBP 4 level: an additional risk factor for experimental fatty liver disease" the 3rd ORT Braude College Research Conference, 8-9 October, 2007, Hagogrim, Israel
36. Hussein O, Abu Gabai K, Grozovski M, Bersudsky I, **Assy N**, karry R, Aviram. "The effect of insulin sensitizers (rosiglitazone and metformin), ezetimibe and valsartan (each alone or in combination) on plasma paraoxanase activity and mRNA expression in experimental rat non - alcoholic fatty liver disease". The 16th International Symposium on Drugs Affecting Lipid Metabolism, 4-7 October, 2007, New York, USA
37. Shatil T, Korem S, **Assy N**, Beniashvili Z, Grozovski M. "The effect of antidiabetic agents and partial hepatectomy on the retinol binding protein 4 level expression in rats with non-alcoholic fatty liver disease undergoing partial hepatectomy" 6th ICRS Annual meeting, 5-6 September, 2007, Caesarea, Israel.
38. **Assy N**, Nasser G, Grosovsky M, Nseir W, Beniashvili Z, and Kamayse L. Soft drink consumption linked with fatty liver (NASH and NAFLD) in patients with no obvious traditional risk factors. EASL, Milan 2008.
39. Grozovski M, Shatil T, Beniashvili Z, Korem S, and **Assy N**. Retinol binding protein-4 expression is up regulated in rats with fatty liver during quiescent and regenerative state and improves with insulin sensitizing agents. EASL, Milan 2008
40. **Assy N**, Dabush S, Ali T, Grozovski M and Nassar F: Serum cholesterol levels at week 4 as predictors of sustained viral response in patients with chronic hepatitis C infection 15th International Symposium on Hepatitis C Virus& Related Viruses, October, 2008, San Antonio, Texas, USA
41. Grozovski_M, Lipshiz G, Korem S, **Assy N**: The effect of insulin sensitizing agents (ISA) on "Protein C" and on Paraoxonase mRNA expression in rats with fatty liver. The Fourth ORT Braude College Interdisciplinary Research Conference, October, 2008, Nazareth Ilit, Israel.
42. **Assy N**, Shatil T and Grozovski M: The effect of insulin sensitizing agents (ISA) on "Protein C" and on Paraoxonase mRNA expression in rats with fatty liver. The 3rd International Falk Symposium, September, 2008, Mainz, Germany



43. **Assy N.**, Nasser G., Kamayse I., Nseir W and Grozovski M. "Soft drink consumption linked with fatty liver in patients without traditional risk factors". EilatIASL 2008
44. International Liver Congress (ICL). 12-15 June, 2008, Hong Kong, China. Grozovski M, Shatil T, Beniashvili Z, Korem S and **Assy N.** "Retinol binding protein 4 expression is up regulated in rats with fatty liver during quiescent and regenerative state and improves with insulin sensitizing agents "International Liver Congress (ICL). 12-15 June, 2008, Hong Kong, China
45. EASL 2009: Abid A, Taha O, Nseir W, Farah R, Grosovski M, **Assy N.** Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome. EASL, Copenhagen 2009
46. Extended Treatment Duration in Chronic hepatitis C Genotype 1 Infected slow - Responders:Final Results of the SUCCESS Study. M. Buti, Y. Lurie, N.G. Zakharova, N.P. Blokhina, A. Horban, C. Sarrazin, L. Balciuniene, R. Chen, X. Yu, R. Faruqi, R. Esteban 44th Annual Meeting of the European Association for the Study of the Liver, Sunday; 12:30-12:45, Hall A2 Copenhagen, Denmark April 26,2009; Hepatology
47. Grozovski M, Djibre A, Daod D, Marmor M, **Assy N.**: Association between excessive soft drink consumption and coronary artery disease and early atherosclerosis, The 5th International Seoul Liver Symposium Liver, September 10-12, 2009, Seoul, Korea
48. Grozovski M, Djibre A, Farah R, Nassar F, Marmor A, **Assy N.**: Non Alcoholic Fatty Liver Diseases and Sub Clinical Coronary Atherosclerosis. 3rd International Congress on Prediabetes and the Metabolic Syndrome, April, 2009, Nice, France
49. Djibre A, MarmorA, Grosovski M, Farah R, Nassar F, and **Assy N.**: Non Alcoholic Fatty Liver Diseases and Sub Clinical Coronary Atherosclerosis The Annual Meeting of the Israeli Society for Research, Prevention and Treatment of Liver Disease, March 5-7, 2009, Kfar Bloom, Israel
50. Grozovski M, Lipez G and **Assy N.**: Effect of insulin sensitizing agents (ISA) on hepatic "protein C" and paraoxonase m-RNA expression in rats with fatty liver the 19th Conference of the APASL, Feb 2009, Hong Kong SAR, China.
51. Kamaysi I, Nseir W, Alexandrov O, Isakson A, 4 Mysh V, 4 Dabbah K, and **Assy N.** Subclinical hepatic encephalopathy in cirrhotic patients is not aggravated by sedation with propofol compared to midazolam. Abstract 277, AASLD Boston 2009.



52. Abu Mouch S, Fireman Z, Jarchovsky J, and **Assy N.** Vitamin D supplement improve SVR in chronic hepatitis C (genotype 1) in naïve patients treated with peginterferon alpha and ribavirin. Abstract LB20 (late breaking), AASLD Boston 2009
53. Nassar F, Nseir William; Alon Marmor Rovman Y, Dvorin I, Djibre A, Grosovski M Daitzman M, **Assy N.** Liver Fat Accumulation Contributes more to the risk of Coronary Artery Disease than Visceral Fat accumulation. Abstract 980 AASLD Boston 2009
54. E.J. Gane, H.L. Chan, G. Choudhuri, D.J. Suh, A. Chutaputti, R. Safadi, T. Tanwandee, S. Thongsawat, **N. Assy**, S.K. Sarin, W. Bao, A. Trylesinski, C. Avila. Treatment of decompensated HBV-Cirrhosis: results from two years randomized trial with Telbivudine or Lamivudine (oral presentation)
55. Abu Mouch, Z. Fireman, J. Jarchovsky, **N. Assy**: Vitamin D supplement improve SVR in chronic hepatitis C (genotype 1) naïve patients treated with interferone and ribavirin (oral presentation).
56. W.A. Long, D. Takov, K. Tchernev, I. Kotzev, A. Rigney, Z. Krastev, S. Stoynov, R. Balabanska, E. Lawitz, Z. Younossi, R. Ghalib, E. Zuckerman, R. Safadi, R. Tur-Kaspa, **N. Assy**, Y. Lurie. Q2 week controlled release interferon alpha -2b +ribavirin reduces flu-like symptoms >50% and provides equivalent efficacy in comparison to weekly pegylated interferon alpha 2b +ribavirin in treatment naïve genotype 1 chronic hepatitis C: results from empower. A randomized open label 12-week comparison in 133 patients (EASL Vienna 2010 oral presentation)
57. Nseir William. Maria Grosovski, and Nimer Assy. fatty liver disease predicts recurrent bacterial infections independently by metabolic syndrome. AASLD Boston 2010
58. A. Ibrahim, S. Abo Mouch, A. Marmor, A. Djibre, **N. Assy**. Retinal vessel diameter, carotid artery IMT and the incidence of coronary artery disease in patients with NAFLD. EASL, Vienna 2010
59. F. Nassar, A. Djibre, A. Marmor, **N. Assy**. Association between excessive soft drink consumption, nonalcoholic fatty liver disease (NAFLD), and coronary artery diseases. EASL 2010 VIENNA
60. Nseir W, Marmor A, Abu Mouch S, Grosovski M, **Assy N.** Association between 25-OH Vitamin D Concentrations and risk of Coronary Artery Disease in Patients with Nonalcoholic Fatty Liver Disease. AASLD; Boston 2010



61. Abu Mouch S and **Assy N.** Vitamin D supplementation improves viral response in chronic hepatitis C patients with genotype 2/3 and high viral load treated with peg interferon alpha-and ribavirin. AASLD; Boston 2010
62. **Assy N.** Nseir W., Rovman Y., Marmor A., Dvorin I., Daitzman M., Djibre A., Grosovski M. Liver Fat Accumulation Contributes more to the risk of Coronary Artery Disease than Visceral Fat. IAGE. Gastroenterology Meeting, Tel Aviv; Hilton 22-06-2010
63. **Assy N.** Nseir W, Rovman Y, Marmor A, Dvorin I, Daitzman M, Djibre A, Grosovski M. Liver Fat Accumulation Contributes more to the risk of Coronary Artery Disease than Visceral Fat. Medical meeting for celebrating 100 years for Ziv Medical Center. Rochpina Octobre 08, 2010
64. Walker A. Long, Eric Lawitz, Yoav Lurie, Zahary Krastev, Dimitar Takov, Konstantin G. Tchernev, Amy Rigney, **Nimer Assy**, Zobair M. Younossi. Adverse Event Reporting During HCV Treatment Via Weekly Clinic Visits Substantially Underestimates Flu Frequency & Severity Compared to Daily ePRO: Results From 133 Patients In EMPOWER study. AASLD, Boston **2010 (Late Breaking)**
65. Nseir W, Marmor A, Abu Mouch S, Grosovski M, **Assy N.** Association between 25-OH Vitamin D Concentrations and risk of Coronary Artery Disease in patients with Nonalcoholic Fatty Liver Disease. The 21st Conference of the Asian Pacific Association for the Study of the Liver (APASL 2011). 17-20 February 2011, QSNCC, Bangkok Thailand
66. Nseir W, Marmor A, Abu Mouch S, Grosovski M, **Assy N.** Association between 25-OH Vitamin D Concentrations and risk of Coronary Artery Disease in patients with Nonalcoholic Fatty Liver Disease. IASL. Eilat 2011
67. Nseir W, Hussein T, Khateeb J, Grosovski M, and **Assy N.** Nonalcoholic Fatty Liver Disease is Strongly Associated with Recurrent Bacterial. Infections Independently by Metabolic Syndrome. EASL2011, Berlin, Germany
68. Nseir W, Morad G, Abu Mouch S, Djibre A, Nassar F, and **Assy N.** Serum HDL and Vitamin D Levels are strongly Associated with SVR in Chronic Hepatitis C Naïve Genotype-1 patients. EASL2011, Berlin, Germany
69. **Assy N.** Djibre A, Dabush S, Ali T, and Abu Mouch S. Vitamin D Supplements Prevent Myalgia and Elevation of CPK in Chronic Hepatitis B Patients Treated with Telbivudine. EASL2011, Berlin, Germany



70. **Assy N.** Vitamin D in chronic liver disease: (Special emphasis on chronic hepatitis c viral infection. BIT 1st Annual world congress of microbes -2011 (WCM-2011). Oral presentation
71. Vintfield Y, Krichevsky L, Svzalb S, Grosovski M, and **Assy N.** Vitamin D and sitagliptin/metformin treatment decrease hepatic triglyceride levels in SK-1 knock out mice with experimental Fatty Liver. Biorefoah -2011. Tel Hai. Kiryat Shemona, Israel
72. Serum HDL and Vitamin D Levels are strongly associated with SVR in chronic hepatitis C naïve genotype-1 patients. Biorefoah , Tel Hai; Kiryat Shemona, 25-10-2011
73. **N Assy**, A Djibre, M Tzuker, S Dabush, T Ali, S Abu Mouch Vitamin D supplement prevents myalgia and elevation of CPK in chronic hepatitis B patients treated with telbivudine. Journal of Hepatology 2011; 54, 704 S283
74. A Marmor, Y Rovman, I Dvorin, A Djibre, M Daitzman, **N Assy**. Fatty liver accumulation contributes more to the risk of coronary artery disease than visceral fat accumulation Journal of Hepatology 2011; 58, 1314 S530-S531
75. W Nseir, J Mograbi, N Di Castro, O Abu-Elheja, Z Abu-Rahmeh, I Khamaysi, M Samara, **N Assy**. On the association between soft drink consumption and Helicobacter pylori infection. Digestive diseases and sciences 2012; 57, 981-986
76. W Nseir, J Khateeb, O Abu-Elheja, B Jihad, **N Assy**. The impact of prior long-term versus short-term statin use on the mortality of bacteraemic patients. Infection 2012; 40, 41-48
77. A Shalata, Y Vintfield, L Krichevsky, S Svzalb, M Grosovski, A Djibre, **N Assy**. The effect of vitamin D and sitagliptin/metformin combination on hepatic fat and triglyceride content in mo-1 mice with fatty liver disease Journal of Hepatology 58, 1315 S531-S531, 2013
78. H Komarov, S Dabah, G Naser, A Marmor, **N Assy**. Nonalcoholic fatty liver disease (NAFLD) is associated with impaired left ventricular diastolic dysfunction and increased mediastinal fat Journal of Hepatology 58, 1348 S542-S543, 2013
79. I Kapnikov, R Farah, N Gibstein, A Djibre, M Grosovski, **N Assy**. Nonalcoholic fatty liver disease (NAFLD) may induce portal hypertension without associated liver fibrosis Journal of Hepatology 2014; 60 (1), S335, P794
80. Rifaat Safadi, Fred M Konikoff, Mahmud Mahamid, Shira Zelber-Sagi, **Nimmer Assy**, Yaakov Baruch. The fatty acid–bile acid conjugate aramchol reduces liver fat



content in patients with nonalcoholic fatty liver disease. Clinical Gastroenterology and Hepatology, 2014; 12 (12), 2085-2091

81. AA Saleh, R Shahien, **N Assy**. Cognitive Dysfunction in Obese Individuals with or without Metabolic Risk Factors. Neurology 2015; 84 (14 Supplement), I12-5A

82. **N Assy**, A Abosaleh, H Assly, M Grosovski, NB Guy P1022: Fibroscan and cognitive dysfunction in obese individuals with metabolic risk factors Journal of Hepatology 2015; 62, S730-S731

83. C Sarr, H Deng, E Snoeck, H Zhang, **N Assy**, Y Lobzin, A Potapov, T Strokova, DH Leung, V Pavlovic, C Wat, Y Jin, N Frey. Population pharmacokinetic analysis of peginterferon alfa-2a (40KD) supports use of BSA-category based dosing in children with chronic hepatitis B: peg-b-active pharmacokinetic sub-study. Hepatology 2016; 63, 929A

84. JM Vierling, A Sobhonslidsuk, G Papatheodoridis, **N Assy**, W Rosenberg, Impact of elbasvir/grazoprevir (EBR/GZR) on health-related quality of life (HRQOL) and fatigue in patients with chronic hepatitis C virus (HCV) infection and inherited blood disorders (IBLD): data from the C-EDGE IBLD study. Journal of Hepatology 2017; 66, S521-S522

85. Abu Shqara Simon, Saad E, Barhoum M and **Assy N**. High SOFA Score and Low serum albumin predicts early mortality in patients with ischemic hepatitis. Department of Medicine A, Galilee Medical Center, Bar Ilan University, The Azrieli Faculty of Medicine, Israel. EASL London 2020

86. Yasin A, **Assy N**, and Sbeit Wisam. Neutrophil to Lymphocytes ratio (NLR), procedure related risk factors (stent and stone crushing) Predicts post-ERCP Pancreatitis. EASL, London England, 2020, Poster

c. Refereed papers in conference proceedings

1. **Assy N**, Rosser BG, Graham GR and Minuk GY. Risk of sedation for upper gastrointestinal endoscopy exacerbating sub clinical hepatic encephalopathy in patients with cirrhosis. Gastrointestinal Endoscopy 1999; 49:690-694 (AASLD)

2. **Assy N**, Adams PC, Myers P, Simon V, Minuk GY, Wall W, Ghent CN. Randomized Controlled

Trial of Total Immunosuppression Withdrawal in Liver Transplant Recipients: Role of Ursodeoxycholic Acid. Transplantation. 2007; 83:1571-1576. (AASLD)



3. Abu Mouch S, Fireman Z, Jarchovs.ky J, and **Assy N.** Vitamin D supplement improve SVR in chronic hepatitis C (genotype 1) in naïve patients treated with peginterferon alpha and ribavirin. WJG 2011 In press; (EASL, AASLD LB)
4. Abid A, Taha O, Nseir W, Farah R, Grosovski M, **Assy N.** Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome. J Hepatol. 2009 ;51:918-24 (EASL)
5. **Assy N**, Gong YW, Zhang M, Pashniak D and Minuk GY. The use of proliferating Cell nuclear antigen as a marker of liver regeneration following partial Hepatectomy in rats. J Lab Clin Med 1998; 131:251-256. (AASLD)
6. **Assy N**, Kaita KDE, Mymin D, Levi C and Minuk GY. Fatty infiltration of the liver in Hyperlipidemic patients. Dig Dis SCI 2000; 45:1929-1934 (AASLD)
7. **Assy N**, Djibre A, Farah R, Grosovski M, Marmor A. Presence of coronary plaques in patients with nonalcoholic fatty liver disease. Radiology. 2010 ;254:393-400 (EASL,AASLD)
8. **Assy N**, Hochberg Z, Amit T, Enat R and Baruch Y. Growth hormone stimulated Insulin like growth factor 1 (IGF-1) and binding protein -3 in liver cirrhosis. J Hepatol 1997; 27: 796-802, EASL, AASLD, IASL
9. Kamaysi Iyad, Nseir William, Alexandrov Olga, Isakson Alex, Mysh Vladimir, Dabbah Kamal, and **Assy Nimer.** Sub clinical hepatic encephalopathy in cirrhotic Patients is not aggravated by sedation with propofol compared to midazolam. J Hepatol. 2011; 54:72-7.
10. AASLD Post graduate course 2018: Predictive value of family history in diagnosis of hereditary hemochromatosis. **Assy N**, Adams PC. Dig Dis Sci. 1997 Jun;42(6):1312-5

7. Funding Sources

From-To	Funding Agency	Title	Amount
2018-2019	Israel Cancer Society	Characterization of recurrent mutation in H2B histone variants as potential novel oncohistone mutations controlling human jumping genes"; In cooperation	75,000 NIS



		with Dr. Idan Cohen	

8. Supervising Graduate and Post-Graduate Students (List of students supervised in the past 5 years and title of their Thesis)

Name of Student	Degree, Years Supervised	Thesis Title
Nasrin Ganim	Masters, 2019	
Eti Azulai	PhD 2018-9 (She didn't finish her thesis due to her daughter's medical problems)	
Natali Silberstein	For final MD project, 2013	
Marva Harpak	For final MD project, 2013	
Joenna Araf	For final MD project, 2014	
Maayan Parkin	For final MD project, 2015	
Nidaa Nasser	For final MD project, 2016	
Joseph Nasser	For final MD project, 2017	
Hiba Nasser	For final MD project, 2018	
Moussa Assy	For final MD project, 2020	
Dr. Walid Kassis	Basic science, clinical research 2020	
Dr. Amad Abu Shkara	Basic science, clinical research 2020	
Dr. Ahmad Yasin	Basic science, clinical research 2019	
Dr. Simon Abu Shkara	Basic science, clinical research 2019	
Dr. Azuar Nagar	Basic science, clinical research 2018	
Dr. Alaa Amasa	Basic science, clinical research 2017	
Dr. Coliada Alexander	Basic science, clinical research 2015	
Dr. Jubran Waal	Basic science, clinical research 2014	
Dr. Alla Ibn Salach	Basic science, clinical research 2014	
Dr. Asla Husam	Basic science, clinical research 2014	
Dr. Insa Kafninov	Basic science, clinical research 2013	



9. Miscellaneous

Additional relevant personal details to describe your academic activities (e.g.

Prizes, Awards, Activities in Research Institutes, Reasons or temporary termination of academic activities etc.).

Date	Membership
	Member of the Israel Association for the Study of the Liver (IASL)
	Member of the European Association for the Study of the Liver (EASL)
	Member of the American Association for the Study of Liver Disease (AASLD)
Date	Patents
July 2009	Grosovski M, Maoz M, Assy N. Therapy of NAFLD utilizing Inula Viscosa Extract. State of Israel. Application Number 199847
Date	Invited Papers
Date	Honors
	An inspiring lecturer award from the National Student Association
2020	“Matzpen” program award (Northern stars) given to two physicians, Azrieli Medical School, Tzfat
2012-2020	Consistently received the Outstanding Lecturer Award, Azrieli Medical School, Tzfat
2017	“Marquis Who’s Who”, Best Author in Medicine

10. Main Research Interests and Achievements

The clinical research unit within the Internal Medicine Ward A of the Galil Medical Center (GMC) of which I am head, has participated in about 60 studies in a variety of internal medicine subjects in the past eight years.

Teaching achievements:

Teaching Student fourth- and fifth-year medical students a course on liver diseases

Teaching for Clerkship in internal medicine

Supervised two MD, one PHD and two Master students' theses



Teaching residents in internal medicine

Director of Bioenergetic course-Bar Ilan university

Services achievement:

Founder of liver clinic in Ziv Medical Center

Acquired a FIBROSCAN apparatus (70,000 euro) for the liver unit

Other Achievements:

Book chapter on soft drink and fatty liver disease

Two registered patents

Over five invited international talks on liver disease

Three letters in the New England Journal of Medicine

Contributing editor in WJG 2010-2013 and reviewer in many top journals

11. Most Significant Past Achievements

Citations: 5783 times; h-index 33; i10-index 58

More than 20 papers in top 5 hepatology journals including Journal of Hepatology 10 papers, Gut 3 papers, Hepatology 2 papers, American Journal of Gastroenterology 5 papers, and New England Journal of Medicine 5 letters.

Most important studies with high clinical implication are:

- 1) Soft drinks are linked with fatty liver disease (J Hepatol 2009)
- 2) Association between cardiovascular disease and fatty liver disease (radiology 2010)
- 3) Vitamin D supplement to peg/rib treatment for patients with HCV viral infection (AASLD LB, EASL ORAL, WJG 2011 in press)
- 4) IGF-1 generation reflects synthetic liver dysfunction in patients with cirrhosis (J Hepatol 1997)
- 5) Sedation with propofil in patients with cirrhosis (J Hepatol 2010, Gastrointestinal Endoscopy 1999)
- 6) VEGF role in liver regeneration (J Hepatol 1999)
- 7) New molecular (PCNA) marker to document extent of liver regeneration (J Lab Clin Med 1998)

12. Future Goals



Further promote my research lab in GMC for MSc and PhD students' theses

Continue clinical medical research with pharmaceutical companies

Keep teaching in the faculty of medicine: clerkships, bioenergetics, liver disease, liver transplantation

Keep on being the most prolific and productive department of internal medicine at Bar Ilan University

B. List of Publications

A. Hypothesis-driven research –

Until last promotion and afterwards

1. **Assy N**, and Adams PC. Predictive value of family history in the diagnosis of hereditary Hemochromatosis. *Dig Dis Sci* 1997; 42:1312-1315.

IF:2.06, Rank: 40/71(Gastro&hepatol). Contribution: A,B,C,D

2. **Assy N**, Hochberg Z, Amit T, Enat R and Baruch Y. Growth hormone stimulated Insulin like growth factor 1 (IGF-1) and binding protein -3 in liver cirrhosis. *J Hepatol* 1997; 27: 796-802

IF: 9.33, Rank: 4/71(Gastro&hepatol). Contribution: A,B,C,D

3. Minuk GY, **Assy N**, Ding LX, Gauthier T, and Pashniak D. Effect of quinolone antibiotics on hepatic growth and protein synthesis following partial hepatectomy in rats. *J Gastroenterol Hepatol* 1997; 12: 54-57. Comment in: *J Gastroenterol Hepatol* 1997; 12: 44-6

IF:2.4, Rank: 33/71(Gastro&hepatol). Contribution: B,D

4. Baruch Y, **Assy N**, Kramsky R, and Enat R. Safety of conversion from cyclosporine sand immune to cyclosporine neoral in stable liver transplant patients. *Transplant Proc* 1998; 30:1852-1853.

IF:0.99, SJR 0,124 (transplant). Contribution: A,B,C,D

5. **Assy N**, Hochberg Z, Enat R, and Baruch Y. Prognostic value of GH-stimulated insulin-Like growth factor -1 (IGF-1) and its binding (IGBP-3) generation in patients with compensated and decompensated liver cirrhosis. *Dig Dis Sci* 1998; 43:1317-1321.

IF: 2.06, Rank: 40/71 (Gastro&hepatol). Contribution: A,B,C,D



- 6 Baruch Y, **Assy N**, Amit T, and Hochberg Z. Spontaneous pharmacokinetics of growth hormone in liver cirrhotic patients. *J Hepatol* 1998; 28:414-419
IF:9.33, Rank: 4/71 (Gastro&hepatol). Contribution: A,B,C,D
7. Kaita KDE, **Assy N**, Gauthier T, and Minuk GY. The beneficial effects of Ciprofloxacin on survival and hepatic regenerative activity in an animal model of Fulminant hepatic failure. *Hepatology* 1998; 27:533-536
IF: 10.88, Rank: 2/71(Gastro&hepatol). Contribution: A,C,D
8. **Assy N**, Gong YW, Zhang M, Pashniak D and Minuk GY. The use of proliferating cell nuclear antigen as a marker of liver regeneration following partial hepatectomy in rats. *J Lab Clin Med* 1998; 131:251-256.
IF: 2.19, Rank: 5/18 (medical laboratory technology category). Contribution: A,B,C,D
9. Baruch Y, **Assy N**, Reisner S, Blendis LM, Berry E, Enat R, and Bomzon A. A pilot study on the hemodynamic effect of short term ursodeoxycholic acid therapy in patients with stable liver cirrhosis. *Am J Gastroenterology*. 1999; 94:3000-3004.
IF: 6.88, Rank: 5/71 (Gastro&hepatol). Contribution: A,B,C,D
10. **Assy N**, Rosser BG, Graham GR and Minuk GY. Risk of sedation for upper gastrointestinal endoscopy exacerbating sub clinical hepatic encephalopathy in patients with cirrhosis. *Gastrointestinal Endoscopy* 1999; 49:690-694.
IF: 5.6, Rank: 7/71 (Gastro&hepatol). Contribution: A,B,C,D
11. **Assy N**, Paizi M, Gaitini D, Baruch Y, and Spira G. Clinical implication of serum VEGF levels in cirrhotic patients with or without portal hypertension. *World J Gastroenterology* 1999; 5: 296-300.
IF: 2.24, Rank: 35/71(Gastro&hepatol). Contribution: A,B,C,D
12. **Assy N**, Gong YW, Zhang M and Minuk GY. Appearance of an inhibitory cell nuclear antigen In rat and human serum during variable degrees of hepatic regenerative activity. *World J Gastroenterol (WJG)* 1999; 5:103-107.
IF: 2.24, Rank: 35/71(Gastro&hepatol). Contribution: A,B,C,D
13. **Assy N**, Spira G, Paizi M, Shankar L, Kraizer Y, Cohen T, Neufeld G, Dabbah B, and Baruch Y. Effect of vascular endothelial growth factor on hepatic regenerative activity following partial hepatectomy in rats. *J Hepatol* 1999; 30:911-915
IF: 9.33, Rank: 4/71(Gastro&hepatol). BY. Research Student. Contribution: A,B,C,D
14. **Assy N**, Kaita KDE, Mymin D, Levi C and Minuk GY. Fatty infiltration of the liver in Hyperlipidemic patients. *Dig Dis SCI* 2000; 45:1929-1934
IF:2.06, Rank: 40/71(Gastro&hepatol). Contribution: A,B,C,D



15. **Assy N**, and Minuk GY. Serum aspartate aminotransferase (AST) values as a useful predictor of histologic features of chronic HCV infection in adults. *Am J Gastroenterology* 2000; 95:1545-1551.

IF: 6.88, Rank: 5/71 (Gastro&hepatol). Contribution: A,B,C,D

16. M Zhang, Gong W, **Assy N**, and GY Minuk. Regulation of alpha fetoprotein and albumin gene expression by gamma-aminobutyric acid receptor agonists in a human hepatocellular carcinoma cell line. *J Hepatol* 2000; 32:85-91

IF: 9.33, Rank: 4/71(Gastro&hepatol). BY. Research Student. Contribution: A,B,C,D

17. Edoute Y, Hussein O, Malberger E, Yerushalmi R, Tibon-Fisher O, **Assy N**. Diagnostic accuracy of direct fine-needle aspiration of liver lesions: a prospective study of 107 patients in peripheral community center with limited technological capability. *Arch gastroenterohepatology* 2001; 20:19-24. (Editorial 20:14-18).

IF:1.67, Rank: 98/114, SJR 0.025 (Gastro&hepatol). Contribution: A,B,C,D

18. Kraizer Y, Mawasi N, Seagal J, Paizi M, **Assy N**, Spira G. Vascular endothelial growth factor and angiopoietin in liver regeneration. *Biochem Biophys Res Com* 2001; 87:209-215

IF:2.59, Rank: 25/121, SJR 0,398 (Biophysics). KY. Research Student. Contribution: A,B,C,D

19. Hussein O, Szvalb S, Van den Akker-Berman LM, and **Assy N**. Liver regeneration is not altered in patients with nonalcoholic steatohepatitis (NASH) when compared to chronic hepatitis C infection with similar grade of inflammation. *Dig Dis Sci*. 2002; 47:1926-31.

IF:2.06, Rank: 40/71(Gastro&hepatol). VL, research student, Contribution: A,B,C,D

20. **Assy N**, Bekirov I, Mejiritsky Y, Solomon L, Szvalb S, and Hussein O. Association between thrombotic risk factors and extent of fibrosis in patients with nonalcoholic Fatty liver disease. *World J gastroenterology* 2005; 11(37):5834-9.

IF: 2.24, Rank: 35/71(Gastro&hepatol). BI, Research student. Contribution: A,B,C,D

21. **Assy N**, Kayal M, Mejiritsky Y, Gorenberg I, Hussein O, and Sorina Schlesinger. The Changes in Functional Renal Mass after a Single Dose of Intravenous Furosemide in Patients with Compensated Liver cirrhosis. *BMC Gastroenterol*. 2006; 6:39.

IF:2.46, Rank: 32/71 (Gastro&Hepatol). A.M. Research Student. Contribution: A,B,C,D

22. **Assy N**, Grozovski M, Bersudsky I, Szvalb S, Hussein O. Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease. *World J Gastroenterol*. 2006; 12:4369-76.

IF: 2.24, Rank: 35/71(Gastro&hepatol). Contribution: A,B,C,D



23. Hussein O, Schlesinger S, Szvalb S, and **Assy N**. Orlistat reverse fatty infiltration and improve hepatic fibrosis in obese patients with nonalcoholic steatohepatitis NASH). *Dig Dis Sci* 2007; 52:2512-9.

IF:2.06, Rank: 40/71(Gastro&hepatol). Contribution: A,B,C,D

24. Hussein O, Gefen Y, Zidan JM, Karochero EY, Luder AS, **Assy N**, Sror ES, Aviram MY. LDL oxidation is associated with increased blood hemoglobin A1c levels in diabetic patients. *Clin Chim Acta*. 2007; 377:114-8.

IF: 2.53, SJR 0.23 (Biomedical Sciences). Contribution: D

25. **Assy N**, Pettigrew N, Lee SS, Chaudhary RK, Johnston J, Minuk GY. Are Chronic Hepatitis C Viral Infections More Benign in Patients with Hemophilia? *Am J Gastroenterol*. 2007;102:1672-6

IF: 6.88, Rank: 5/71 (Gastro&hepatol). Contribution: A,B,C,D

26. **Assy N**, Adams PC, Myers P, Simon V, Minuk GY, Wall W, Ghent CN. Randomized Controlled Trial of Total Immunosuppression Withdrawal in Liver Transplant Recipients: Role of Ursodeoxycholic Acid. *Transplantation*. 2007; 83:1571-1576.

IF:3.67, Rank: 11/40 (Surg). Contribution: A,B,C,D

27. **Assy N**, Hussein O, Khalil A, Luder A, Szvalb S, Paizi M, Spira G. The beneficial effect of aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of cirrhosis. *Dig Dis Sci*. 2007; 52:1187-93

IF:2.06, Rank: 40/71(Gastro&Hepatol). A.K. Research Student. Contribution: A,B,C,D

28. Hussein O, Grosovski M, Lasri E, Svalb S, Ravid U, **Assy N**. Monounsaturated fat decreases hepatic lipid content in non-alcoholic fatty liver disease in rats. *World J Gastroenterol*. 2007; 13:361-368

IF: 2.24, Rank: 35/71(Gastro&hepatol). Contribution: A,B,C,D

29. **Assy N**, Nasser G, Kamayse I, Nseir W, Beniashvili Z, Djibre A, Grosovski M. Soft drink consumption linked with fatty liver in the absence of traditional risk factors. *Can J Gastroenterol*. 2008; 22:811-6.

IF:1.55, Rank: 49/71 (Gastro&hepatol). Contribution: A,B,C,D

30. **Assy N**, Pruzansky Y, Gaitini D, Shen Orr Z, Hochberg Z, Baruch Y. Growth hormone-stimulated IGF-1 generation in cirrhosis reflects hepatocyte cellular dysfunction. *J Hepatol*. 2008; 49:34-42

IF:9.33, Rank: 4/71 (Gastro&hepatol). BY. Research Student. Contribution: A,B,C,D



31. **Assy N**, Beniashvili Z, Djibre A, Nasser G, Grosovski M, Nseir W. Lower baseline ALT cut-off values and HBV DNA levels better differentiate HBeAg- chronic hepatitis B patients from inactive chronic carriers. *World J Gastroenterol.* 2009; 15:3025-31
IF: 2.24, Rank: 35/71(Gastro&hepatol). Contribution: A,B,C,D
32. Aid A, Taha O, Nseir W, Farah R, Grosovski M, **Assy N**. Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome. *J Hepatol.* 2009; 51:918-24
IF:9.33, Rank: 4/71 (Gastro&hepatol). A.A. Research Student. Contribution: A,B,C,D
33. **Assy N**, Djibre A, Farah R, Grosovski M, Marmor A. Presence of coronary plaques in patients with nonalcoholic fatty liver disease. *Radiology.* 2010; 254:393-400
IF:6.06, Rank: 2/40 (Radiology). D.A. Research Student. Contribution: A,B,C,D
34. Nseir W, Khateeb J, Tatour I, Haiek I, and **Assy N**. Long Term Statin Therapy May Reduce the Severity of Chronic Gastritis. *Helicobacter* 2010; 15:510-5.
IF:3.1, Rank: 10/25 (Gastro). Research Student. Contribution: A,B,C,D
35. Kamaysi I, Nseir W, Alexandrov O, Isakson A, Mysh V, Dabbah K, and **Assy N**. Subclinical hepatic encephalopathy in cirrhotic Patients is not aggravated by sedation with propofol compared to midazolam. *J Hepatol.* 2011; 54:72-7.
IF:9.33, Rank: 4/71 (Gastro&hepatol). A.O. Research Student. Contribution: A,B,C,D
36. Nseir W, Hussein T, Khateeb J, Grosovski M, and **Assy N**. Fatty Liver Disease is Associated with Recurrent Bacterial Infections Independently of Metabolic Syndrome. *Dig Dis Sci.* 2011; 56:3328-3334
IF:2.06, Rank: 40/71(Gastro&hepatol). Contribution: A,B,C,D

Since last promotion

1. **Assy N**, Saad E, Basheer M, Assy Najib and Sbeit W. New Predictor of Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis. *Clin Gastroenterol Int.* 2021; 3(1): 1017.
2. Basheer M, Saad E and **Assy N**. Low (HDL) Lipoprotein Levels is Strongly Correlated with The Severity of Covid -19 Pneumonia. *Japanese J Gastro Hepato.* 2021; V5(12): 1-2
3. Basheer M, Saad E and **Assy N**. Methylprednisolone Decrease In - Hospital Mortality in Patients with COVID-19 Pneumonia. *Japanese J Gastro Hepato.* 2021; V5(12): 1-1



4. Lim JJ, Nilsson AC, Silverman M, Assy N, Kulkarni P, McBride JM, Deng R, Li C, Yang X, Nguyen A, Horn P, Maia M, Castro A, Peck MC, Galanter J, Chu T, Newton EM, Tavel JA. A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of MHAA4549A, a Monoclonal Antibody, plus Oseltamivir in Patients Hospitalized with Severe Influenza A Virus Infection. *Antimicrob Agents Chemother.* 2020; 64:e00352-20.

5. Kadah A, Khoury T, Mahamid M, **Assy N**, Sbeit W. Predicting common bile duct stones by non-invasive parameters. *Hepatobiliary Pancreat Dis Int.* 2020. pii: S1499-3872(19)30221-8.

IF 1.576 Rank: 78/84 (Gastroenterology & Hepatology). Contribution: C, D

6. Ruilope LM, Agarwal R, Anker SD, Bakris GL, Filippatos G, Nowack C, Kolkhof P, Joseph A, Mentenich N, Pitt B; FIGARO-DKD study investigators. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. *Am J Nephrol.* 2019; 50:345-356

IF 2.961 Rank: 20/80 (Urology & Nephrology). Contribution: B,D

7. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, Kolkhof P, Ferreira AC, Schloemer P, Filippatos G; on behalf of the FIDELIO-DKD study investigators; FIDELIO-DKD study investigators. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. *Am J Nephrol.* 2019;50:333-344

IF 2.961 Rank: 20/80 (Urology & Nephrology). Contribution: B,D

8. Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S; VARSITY Study Group. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. *N Engl J Med.* 2019 ;381:1215-1226.

IF 70.670 Rank: 1/160 (Medicine, General & Internal). Contribution: B,D

9. Perez S, Kaspi A, Domovitz T, Davidovich A, Lavi-Itzkovitz A, Meirson T, Alison Holmes J, Dai CY, Huang CF, Chung RT, **Nimer A**, El-Osta A, Yaari G, Stemmer SM, Yu ML, Haviv I, Gal-Tanamy M. Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals. *PLoS Genet.* 2019; 15:e1008181.

IF 5.224 Rank: 23/173 (Genetics & Heredity). Contribution: B,D

10. Gozlan Y, Bucris E, Shirazi R, Rakovsky A, Ben-Ari Z, Davidov Y, Veizman E, Saadi T, Braun M, Cohen-Naftaly M, Shlomai A, Shibolet O, Zigmond E, Katchman H, Menachem Y, Safadi R, Galun E, Zuckerman E, **Nimer A**, Hazzan R, Maor Y, Saif AM, Etzion O, Lurie Y,



Mendelson E, Mor O. High frequency of multiclass HCV resistance-associated mutations in patients failing direct-acting antivirals: real-life data. Antivir Ther. **2019**; 24:221-228.

IF 2.305 Rank: 23/36 (Virology). Contribution: B,D

11. Eliyahu S, Sharabi O, Elmedvi S, Timor R, Davidovich A, Vigneault F, Clouser C, Hope R, **Nimer A**, Braun M, Weiss YY, Polak P, Yaari G, Gal-Tanamy M. Antibody Repertoire Analysis of Hepatitis C Virus Infections Identifies Immune Signatures Associated With Spontaneous Clearance. Front Immunol. **2018**; 9:3004.

IF 4.716 Rank: 43/158 (Immunology). Contribution: B,D

12. Zelber-Sagi S, Bord S, Dror-Lavi G, Smith ML, Towne SD Jr, Buch A, Webb M, Yeshua H, **Nimer A**, Shibolet O. Role of illness perception and self-efficacy in lifestyle modification among non-alcoholic fatty liver disease patients. World J Gastroenterol. **2017**; 23:1881-1890.

IF 3.411 Rank: 35/84 (Gastroenterology & Hepatology). Contribution: A,B,C,D

13. Gozlan Y, Ben-Ari Z, Moscona R, Shirazi R, Rakovsky A, Kabat A, Veizman E, Berdichevski T, Weiss P, Cohen-Ezra O, Lurie Y, Gafanovich I, Braun M, Cohen-Naftaly M, Shlomai A, Shibolet O, Zigmond E, Zuckerman E, Carmiel-Haggai M, **Nimer A**, Hazzan R, Maor Y, Kitay-Cohen Y, Shemer-Avni Y, Kra-Oz Z, Schreiber L, Peleg O, Sierra S, Harrigan PR, Mendelson E, Mor O. HCV genotype-1 subtypes and resistance-associated substitutions in drug-naive and in direct-acting antiviral treatment failure patients. Antivir Ther. **2017**; 22:431-441.

IF 2.305 Rank: 23/36 (Virology). Contribution: B,D

14. Frank Wolf M, Peleg D, Kariv Silberstein N, **Assy N**, Djibre A, Ben-Shachar I. Correlation between changes in liver stiffness and preeclampsia as shown by transient elastography. Hypertens Pregnancy. **2016**; 35:536-541.

IF 1.736 Rank: 53/83 (Obstetrics & Gynecology). Contribution: A,B,C,D

15. Flisiak R, Kawazoe S, Znoyko O, **Assy N**, Gadano A, Kao JH, Lee KS, Zwirter R, Portsmouth S, Dong Y, Xu D, Kumada H, Srinivasan S. Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b. J Interferon Cytokine Res. **2016**; 36:635-643.

IF 1.774 Rank: 134/158 (Immunology). Contribution: B,D

16. Farah R, Gilbey P, Grozovski M, Asli H, Khamisy-Farah R, **Assy N**. Antioxidant Enzyme Activity and Cognition in Obese Individuals with or without Metabolic Risk Factors. Exp Clin Endocrinol Diabetes. **2016**; 124:568-571

IF 1.927 Rank: 115/145 (Endocrinology & Metabolism). Contribution: A,B,C,D



17. Lalazar G, Mizrahi M, Turgeman I, Adar T, Ben Ya'acov A, Shabat Y, **Nimer A**, Hemed N, Zolotarova L, Lichtenstein Y, Lisovoder N, Samira S, Shalit I, Ellis R, Ilan Y. Oral Administration of OKT3 MAAb to Patients with NASH, Promotes Regulatory T-cell Induction, and Alleviates Insulin Resistance: Results of a Phase IIa Blinded Placebo-Controlled Trial. J Clin Immunol. **2015**; 35:399-407.

IF 4.128 Rank: 54/158 (Immunology). Contribution: B, D

18. Safadi R, Konikoff FM, Mahamid M, Zelber-Sagi S, Halpern M, Gilat T, Oren R; FLORA Group. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. **2014**; 12:2085-91.e1.

IF 7.958 Rank: 8/84 (Gastroenterology & Hepatology). Contribution: A,B,C,D

19. Dabbah S, Komarov H, Marmor A, **Assy N**. Epicardial fat, rather than pericardial fat, is independently associated with diastolic filling in subjects without apparent heart disease. Nutr Metab Cardiovasc Dis. **2014** ;24:877-82

IF 3.340 Rank: 33/86 (Nutrition & Dietetics). Contribution: A,B,C,D

20. Zelber-Sagi S, Webb M, **Assy N**, Blendis L, Yeshua H, Leshno M, Ratziu V, Halpern Z, Oren R, Santo E. Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification. World J Gastroenterol. **2013**; 19:57-64.

IF 3.411 Rank: 35/84 (Gastroenterology & Hepatology). Contribution: A,B,C,D

21. Josef P, Ali I, Ariel P, Alon M, **Nimer A**. Relationship between retinal vascular caliber and coronary artery disease in patients with non-alcoholic fatty liver disease (NAFLD). Int J Environ Res Public Health. **2013**; 10:3409-23.

IF 2.14, Rank 73/180 ('Public, Environmental & Occupational Health'). Contribution: A,B,C,D

22. **Nimer A**, Mouch A. Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients. World J Gastroenterol. **2012**; 18:800-5.

IF 3.411 Rank: 35/84 (Gastroenterology & Hepatology). Contribution: A,B,C,D

23. Nseir W, Mograbi J, Abu-Elheja O, Bishara J, **Assy N**. The impact of prior long-term versus short-term statin use on the mortality of bacteraemic patients. Infection. **2012** ;40(1):41-8.

IF 2.927 Rank: 39/89 (Infectious Diseases). Contribution: A,B,C,D

24. Nseir W, Mograbi J, Di Castro N, Abu-Elheja O, Abu-Rahmeh Z, Khamaysi I, Samara M, **Assy N**. On the association between soft drink consumption and Helicobacter pylori infection. Dig Dis Sci. **2012** ;57:981-6.



IF 2.937 Rank: 48/84 (Gastroenterology & Hepatology). Contribution: A,B,C,D

25. Assy N, Basher W, Chetver L, Shnaider J, Zidan J. First-line treatment with capecitabine combined with irinotecan in patients with advanced colorectal carcinoma: a phase II study. J Clin Gastroenterol. 2012; 46:e27-30.

IF 2.724 Rank: 54/84 (Gastroenterology & Hepatology). Contribution: C,D

26. Elias W, Assy N, Elias I, Toledo T, Yassin M, Bowirrat A. The detrimental danger of Water-Pipe (Hookah) transcends the hazardous consequences of general health to the driving behavior. J Transl Med. 2012;10:126.

IF 4.098 Rank: 41/136 (Medicine, Research & Experimental). Contribution: A,B,C,D

27. Abu-Mouch S, Fireman Z, Jarchovsky J, Zeina AR, Assy N. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World J Gastroenterol. 2011; 17:5184-90.

IF 3.411 Rank: 35/84 (Gastroenterology & Hepatology). Contribution: A,B,C,D

B. Clinical Descriptive Research (i.e., retrospective studies)

Until last promotion and afterwards

1. Assy N, Blumenfeld Z, Berkovitz D, Nave Y, Kramsky R, Rosenthal E, Enat R, and Baruch Y. Long term follow up of liver transplant patients in a non-liver transplantation center. Transplant Proceed 1997; 29:2664-2666.

IF: 0.99, Rank: x/y (Transplant). Contribution: A,B,C,D

2. Edoute Y, Malberger E, Tibon-Fisher O, Assy N. Non- imaging-guided fine needle aspiration of liver lesions: A retrospective study of 279 patients. World J Gastroenterology (WJG) 1999; 5:98-103. Invited Commentary WJG 1999; 5:98-102.

IF: 2.24, Rank: 35/71(Gastro&hepatol). Contribution: A,B,C,D

3. Hoffman R, Assy N, Lanir N, Brenner B, Baruch Y. Budd-Chiari syndrome associated with factor V Leiden mutation: A report of 6 patients. Liver Transpl Surg 1999; 5:96-100.

IF:3.05, Rank: 10/25 (Transplantation). Contribution: A,B,C,D

4. Assy N, Minuk GY. A comparison between previous and present histologic assessments of chronic hepatitis C viral infection in humans. World J Gastroenterology 1999; 5:107-111.

IF: 2.24, Rank: 35/71(Gastro&hepatol). Contribution: A,B,C,D

Since last promotion



1. Saad E, Sbeit W, Barhoum M, Levy G, **Assy N**. Seasonal Patterns of Acute Esophageal Variceal Bleeding in Patients with Liver Cirrhosis. Japanese Journal of Gastroenterology and Hepatology **2020, Jan 22**

IF 1.690, Rank (Gastroenterology & Hepatology), (A,B,C,D)

2. Meerson A, Najjar A, Saad E, Sbeit W, Barhoum M, **Assy N**. Sex Differences in Plasma MicroRNA Biomarkers of Early and Complicated Diabetes Mellitus in Israeli Arab and Jewish Patients. Noncoding RNA. **2019**;5(2). pii: E32.

IF2.03 , Rank 7784 (Biochemistry; Genetics; Molecular Biology) (A,B,C,D)

3. Shalata A, Mahroom M, Milewicz DM, Limin G, Kassum F, Badarna K, Tarabeih N, **Assy N**, Fell R, Cohen H, Nashashibi M, Livoff A, Azab M, Habib G, Geiger D, Weissbrod O, Nseir W. Fatal thoracic aortic aneurysm and dissection in a large family with a novel MYLK gene mutation: delineation of the clinical phenotype. Orphanet J Rare Dis. **2018**;13(1):41.

IF 3.687 Rank: 48/173 (Genetics & Heredity), (D)

C. Case reports

Until last promotion and afterwards

1. **Assy N**, Rosenthal E, Hazani A, Etzioni A, Baruch Y. Human parvovirus B19 infection 1 associated with idiopathic thrombocytopenic purpura in a child following liver transplantation. J Hepatol 1997;27:934-936.

IF:9.33, Rank: 4/71 (Gastro&hepatol). Contribution: A,B,C,D

2. Edoute Y, Lachter J, Furman E, and **Assy N**. Severe cholestatic jaundice induced by EBV infection in the elderly. J Gastroenterol Hepatol 1998; 13:821-824.

IF:2.4, Rank: 33/71(Gastro&hepatol). Contribution: A,B,C,D

3. Miron D, Olshinsky A, **Assy N**, Zuker M, Efrat M, Hussein O. Plasmodium and Borrelia coinfection. J Travel Med 2004; 11:115-116.

IF:1.47, Rank: ? (Infection disease). Contribution: D

4. **Assy N**, Khair G, Sorina Schlesinger, and Osamah Hussein. Severe cholestatic jaundice in the elderly induced by low dose amiodarone. Dig Dis Sci 2004, 49: 450.

IF:2.06, Rank: 40/71(Gastro&hepatol). Contribution: A,B,C,D

5. **Assy N**, Schlesinger S, Miron D, Hussein O. Cycling of antibiotics for the prophylaxis of recurrent spontaneous bacterial peritonitis in a cirrhotic patient. World J Gastroenterology 2005; 11:6407-6408.

IF: 2.24, Rank: 35/71(Gastro&hepatol). Contribution: A,B,C,D



6. **Assy N**, Gefen H, Schlesinger S, and Hussein O. The beneficial effect of N-acetylcysteine and ciprofloxacin therapy on the outcome of ischemic fulminant hepatic failure *Dig Dis Sci.* 2007 Apr 5
IF:2.06, Rank: 40/71(Gastro&hepatol). Contribution: A,B,C,D
7. **Assy N**, Gefen H, Schlesinger S, and Karim W. Reactivation versus primary CMV infection after splenectomy in immunocompetent patient. *Dig Dis Sci* 2007; 2007 Apr 12.
IF:2.06, Rank: 40/71(Gastro&hepatol). Contribution: A,B,C,D
8. Benyashvili Z, Djibre A, **Assy N**. Fulminant Kliebsella pneumoniae pneumonia in immunocompromised patient. *Clinical Medicine* 2008;1: 81-82 (A,B,C,D; **viewed at libertas academia 1298 times**)
IF:1.04, Rank: ? (Gastro&hepatol). Contribution: A,B,C,D
9. Nassar F, Nasser M and **Assy N**, Epstein-Barr virus-associated fulminant hepatic failure and autoimmune hemolytic anemia. *Gastrohep.com* 19 December 2008
10. Samuel N, Ezri Y, Farah R, Vacksman I, Hussein A, Rubinstein O, **Assy N**. Acute Aflatoxicosis Resulting in Fulminant Hepatic Failure and Rhabdomyolysis. *Gastroenterology Research* 2009, 2: 48-50
11. Nassar F, Vaisbein E, and **Assy N**. Autoimmune hepatitis - SLE overlap syndrome. *Gastrohep.com* 30 January 2009
12. G Murad, R Shaheen, R Farah, and **N Assy**, Severe acute cholestatic hepatitis with encephalitis induced by Epstein-Barr virus infection. *Gastrohep.com*. 22 April 2009
13. Djibre A, Zohar S and **Assy N**, Acute fatty liver of pregnancy. *Gastrohep.com* 30 March 2010
14. Djibre A, Szvalb S and **Assy N**, D-penicillamine-induced skin elastosis perforans serpiginosa. *Gastrohep.com* 19 April 2010

Since last promotion

1. W Sbeit, N **Assy**, A Kadah, M Farraj, M Barhoum, M Musa, M Shiller Foley Catheter Gastric Tube Feeding Migration as a Cause of Acute Pancreatitis. *Journal of Pancreas*. **2017**; 18, 170-174
2. A Djibre, **N Assy**: Recurrent postpartum autoimmune hepatitis *Gastrohep.com* 11 June **2013**

D. Review Papers



Until last promotion and afterwards

1. Minuk GY and **Assy N.** The consequences of hepatitis C viral infections. *Can J Gastroenterology* 1995; 9:373-376.

IF: 1.55, Rank: 49/71 (Gastro&hepatol). Contribution: A,B,C,D

2. **Assy N.**, and Minuk GY. Liver regeneration: methods for monitoring and their applications. *J Hepatol* 1997;26:945-952.

IF: 9.33, Rank: 3/71 (Gastro&hepatol). BY. Research Student. Contribution: A,B,C,D

3. **Assy N.**, and Minuk GY. Liver Disease in pregnancy. *J Am Coll Surg* 1997; 183:643-653.

IF: 4.2, Rank: 7/40 (Surgery). Contribution: A,B,C,D

4. **Assy N.**, Jacob G, Spira G, and Edout Y: Diagnostic approach to patients with cholestatic jaundice. *World J Gastroenterology (WJG)* 1999; 5:252-262. (Invited review).

IF: 2.24, Rank: 35/71(Gastro&hepatol). Contribution: A,B,C,D

5. Cohen AJ, **Assy N.**, Moser M, and Minuk GY. Viral hepatitis and the surgeon. *HPB* 2005; 7:56-64.

IF:1.285, Rank: 54/71 (Gastro&hepatol. Contribution: A,B,C,D

6. **Assy N.**, Assy NN, Samuel N, Lerman A, Nseir W. Approach to solid liver masses in the cirrhotic patient. *Gastroenterology research*. 2009,2: 259-267

IF: 0.5, Rank: ? (Gastro&hepatol). Contribution: A,B,C,D

7. **Assy N.**, Nassar F, Nasser G, Grosovski M. Olive oil consumption and non-alcoholic fatty liver disease. *World J Gastroenterol.* 2009 ;15:1809-15.

IF: 2.24, Rank: 35/71 (Gastro&hepatol). Contribution: A,B,C,D

8. **Assy N.**, Nasser G, Djibre A, Beniashvili Z, Elias S, Zidan J. Characteristics of common solid liver lesions and recommendations for diagnostic workup. *World J Gastroenterol.* 2009; 15:3217-27

IF: 2.24, Rank: 35/71 (Gastro&hepatol). Contribution: A,B,C,D

9. Nseir W, Nassar F, **Assy N.** Soft drinks consumption and nonalcoholic fatty liver disease. *World journal Gastroenterol*, 2009 Jul 14;15 :3217-27 (A,B,C,D): [Cited in wikipedia](#)

IF: 2.24, Rank: 35/71 (Gastro&hepatol). Contribution: A,B,C,D

10. Nseir W, Shalata A, Marmor A, and **Assy N.** Mechanisms Linking Non-Alcoholic Fatty Liver

Disease with Coronary Artery Disease. *Dig Dis SCI* 2011;56:3439-49.

IF:2.06, Rank: 40/71 (Gastro&hepatol). Contribution: A,B,C,D



11. **Assy N.** Nutritional recommendations for patients with non-alcoholic fatty liver diseases.
World J Gastroenterol. 2011; 17:3375-6

Since last promotion

1. Elias S, Wisam S, Luai A, Massad B, **Nimer A.** Lipotoxicity in Obesity: Benefit of Olive Oil. Adv Exp Med Biol. 2017;960:607-617.
IF 2.126 Rank: 86/136 (Medicine, Research & Experimental), (A,B,C,D)
2. Nseir W, Hellou E, **Assy N.** Role of diet and lifestyle changes in nonalcoholic fatty liver disease. World J Gastroenterol. 2014; 20:9338-44.
IF 3.411 Rank: 35/84 (Gastroenterology & Hepatology), (A,B,C,D)

E. Other Publications

Until last promotion and afterwards

1. Edoute Y, Malberger E, Tibon-Fisher O, **Assy N.** Non-imaging-guided fine needle aspiration of liver lesions: Invited Commentary WJG 1999; 5:98-102.
IF: 2.24, Rank: 35/71 (Gastro&hepatol). Contribution: A,B,C,D
2. **Assy N**, Schlesinger S, Hussein O. Acute hepatitis with extremely high ferritin levels and Still's disease. J Hepatol. 2001; 35:830-831.
IF: 9.33, Rank: 3/71 (Gastro&hepatol). Contribution: A,B,C,D
3. **Assy N**, Hussein. Peg interferon and lamivudine for hepatitis B O. New Engl J Med. 2004; **30;** 351(27):2879;
IF: 53.4, Rank: 1/151 (medicine, general & internal). Contribution: A,B,C,D
4. **Assy N**, Schlesinger S, and Hussein O. Elevated plasma protein C correlates with the presence of fatty liver (NASH and NAFLD). Gut 2005;54(5):729
IF: 10.6, Rank: 3/71 (Gastro&hepatol). Contribution: A,B,C,D
5. **Assy N**, Schlesinger S, Miron D, Hussein O. Cycling of antibiotics for the prophylaxis of recurrent spontaneous bacterial peritonitis in a cirrhotic patient. World J Gastroenterology 2005; 11:6402-6402
IF: 2.24, Rank: 35/71 (Gastro&hepatol). Contribution: A,B,C,D
6. **Assy N**, Schlesinger S, Hussein O. Beta-blockers to prevent gastro esophageal varices in cirrhosis. N Engl J Med 2006; 23; 353:1318.
IF: 53.4, Rank: 1/151 (medicine, general & internal). Contribution: A,B,C,D
7. **Assy N**, Embo O. Peginterferon and ribavirin for hepatitis C. N Engl J Med 2007; 22;356:1269
IF: 53.4, Rank: 1/151 (medicine, general & internal). Contribution: A,B,C,D



8. **Assy N**, Beniashvili Z, Nseir W, and Empon Oscaar. Day-case liver biopsy: a prospective study of 300 cases. *Am J Gastroenterology*: 2007; 2007; 102:2611-2
IF: 6.88, Rank: 5/71 (Gastro&hepatol). Contribution: A,B,C,D
9. **Assy N**, Adams P, and Ghent CN. A randomized controlled trial of total immunosuppression withdrawal in stable liver transplant recipients. *Gut* 2007; 56:304-312.
IF: 10.6, Rank: 3/71 (Gastro&hepatol). Contribution: A,B,C,D
10. **Assy N**, Nseir W. Letter to the Editor: Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome. *J Hepatol* 2010; 52:951-954
IF: 9.33, Rank: 3/71 (Gastro&hepatol). Contribution: A,B,C,D
11. **Assy N**, Khamayse I. Sub clinical hepatic encephalopathy in cirrhotic patients is not aggravated by sedation with propofol compared to midazolam: A randomized controlled study *Journal of Hepatology* JHEPAT-D-10-00373R3. *J Hepatol*. 2010 Dec
IF: 9.33, Rank: 3/71(Gastro&hepatol). Contribution: A,B,C,D
12. Zelberg-Sagi S, Ratziu V, Oren R. Nutritional and physical activity in NAFLD: An overview of the epidemiological evidence. *WJG* 2011, (17: 1-0000). Series Editor
IF: 2.24, Rank: 35/71(Gastro&hepatol). Contribution: A,B,C,D;
13. **Assy N**. Nutritional recommendation of patients with Nonalcoholic fatty liver diseases (NAFLD). *World J Gastroenterol* 2011 March 14; 17(10): -0000: Invited Editorial to *WJG* 2010 as an expert in the field (Highlights 2011):
IF: 2.24, Rank: 35/71(Gastro&hepatol). Contribution: A,B,C,D,

Since last promotion

Letters to the Editor

Sbeit W, **Assy N**, Farraj M, Kadah A, Shiller M. Comment on ACG and CAG Clinical Guidelines for Management of Dyspepsia. *Am J Gastroenterol*. **2018**; 113:623-624.

IF 10.241 Rank: 7/84 (Gastroenterology & Hepatology), (C,D)

Assy N, Barhoum M. Sofosbuvir and Velpatasvir for Patients with HCV Infection [Letter]. *N Engl J Med*. **2016** ;374:1687

IF 70.670 Rank: 1/160 (Medicine, General & Internal) (A,B,C,D)

Assy N, Saad E, Basheer M, Assy Najib and Sbeit W. New Predictor of Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis. *Clin Gastroenterol Int*. **2021**; 3(1): 1017.

Basheer M, Saad E and **Assy N**. Low (HDL) Lipoprotein Levels is Strongly Correlated with The Severity of Covid -19 Pneumonia. *Japanese J Gstro Hepato*. **2021**; V5(12): 1-2

Basheer M, Saad E and **Assy N**. Methylprednisolone Decrease In - Hospital Mortality in Patients with COVID-19 Pneumonia. *Japanese J Gstro Hepato*. **2021**; V5(12): 1-1



Papers with no IF

1. **Assy N.** Consequence of Chronic HCV infection. Maccabi Health Service Letters. 1997
2. Kayal M, Dabus S, **Assy N.** Changes in Kidney Function (GFR) after Furosemide administration in Patients with compensated cirrhosis. **The Medical 2009**
3. Dabush S, Djibree A, Nseir W, **Assy N.** Pharmacologic treatment of fatty liver.

The Medical 2010

4. **Assy N**, Abu Mouch S. Vitamin D could help fight hepatitis C. Vitamin D may also be key to curing hepatitis. But Israelis, especially the ultra-Orthodox, are woefully deficient. Haaretz Daily 14.01.2010
5. **Assy N**, Assy N, Samuel N, Lerman A, Nseir W. Approach to solid liver mass in the cirrhotic patient. **Gastroenterology Research**; vol2, N5, OCT 2009
6. Samuel N, Ezri Y, Farah R, Vacksman I, Hussein A, Rubinstein O, **Assy N.** Acute aflatoxicosis resulting in fulminant hepatic failure and rhabdomyolysis. **Gastroenterology Research** VOL2, N 1, FEB 2009
5. Soda Drinks Cause Liver Damage. Sweetened drinks may cause long-term liver damage, advises Israeli physician. Switching to water is the best preventive measure. by Karin Kloosterman. Israel21c. Published: 09/08/09. <http://israel21c.org/health/israeli-study-soda-and-fruit-juice-drinks-cause-liver-damage>
6. **Assy N:** Pharmacological treatment in NAFLD. Led by Oren R; **Medical Media**, fatty liver 2009

F. Books

Until last promotion and afterwards

1. **Assy N**, Nassar F and Grosovski M. Monounsaturated Fat Enriched with Olive Oil in Non-alcoholic Fatty Liver Disease. In: Victor R. Preedy and Ronald Ross Watson, editors, **Olives and Olive Oil in Health and Disease Prevention. Oxford:** Academic Press, 2010, pp. 1151-1156. ISBN: 978-0-12-374420-3 Academic Press. © 2010 Copyright Elsevier Inc
2. Nseir W, and **Assy N.** Mechanisms Linking Non-Alcoholic Fatty Liver Disease with Coronary Artery Disease. "Coronary Angiography / Book 3", ISBN 979-953-307-236-3.



Full Chapter Submission: 31 March, 2011. InTech - Open Access Publisher. Email: zgela@intechweb.org. Web: <http://www.intechweb.org/>

Since last promotion

1. Azulay EE, **Assy N**, Cohen I (November 2018) **Interleukin-1**. In: eLS Immunology. John Wiley & Sons, Ltd : Chischester. DOI:10.1002/9780470015902.a0028193
2. Elias S., Masad B., **Nimer A.** (2017) **Serum Biomarkers for Evaluating Portal Hypertension**. In: Patel V., Preedy V. (eds) Biomarkers in Liver Disease. Biomarkers in Disease: Methods, Discoveries and Applications. Springer, Dordrecht: 153-167
3. Elias S., Wisam S., Luai A., Massad B., **Nimer A.** **Lipotoxicity in Obesity: Benefit of Olive Oil**. In: Engin A., Engin A. (eds) Obesity and Lipotoxicity. Advances in Experimental Medicine and Biology. **Springer, Cham** 2017; 960: 607-617
4. **N Assy**, F Adawi. W Nseir. **Fructose synthesis function and health implications**. Nutrition and diet research progress. Food science and Tehnology . 2012 3rd Quarter page 101-106 chapter 5; isbn 978-1-62081-126-9

G. Papers in press

Since last promotion

1. Saad E, Barhoum M, Asly M, and **Assy N**. Complete blood count (CBC) parameters as a predictor of the severity of chronic obstructive pulmonary disease (COPD) exacerbation **2020**
2. Dalia David Niv, Lihi Grinberg, Soliman khatib, Jacob Vaya, **Assy Nimer**, David Karasik. Intestinal inflammation and NAFLD induced by western diet in the zebrafish model **2020**
3. Jeremy J Lim, Anna C Nilson, Michael Silverman, **Nimer Assy**, et al. a phase 2 double-blind placebo controlled trial of MHAA4549A, a monoclonal antibody, plus oseltamivir inpatients hospitalized with severe influenza A infection. Target Journal: Lancet Respiratory Medicine **2020**
4. D. Hanfelt-Goade, N. Maimon , A. Nimer⁴, F. Riviere, E. Catherinot , M. Ison, S.H. Jeong, E. Walsh, A. Gafter-Gvili , S.R. Nama , P. Napora et all . A phase 2b, randomized, double blind, placebo controlled trial of presatovir (GS-5806), a novel oral respiratory syncytial virus (rsv) fusion inhibitor, for the treatment of RSV in hospitalized adults. American Journal of Respiratory and Critical Care Medicine 2018;197:A4457